Elicio Therapeutics Files 8-K: Material Agreement, Debt, Equity Sales
Ticker: ELTX · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, debt, equity-sale
TL;DR
Elicio Therapeutics just dropped an 8-K: new deal, debt, and equity sales. Big moves!
AI Summary
Elicio Therapeutics, Inc. announced on June 3, 2025, that it entered into a material definitive agreement. The company also disclosed the creation of a direct financial obligation and unregistered sales of equity securities. This filing also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions including a new agreement, potential debt, and equity issuance, which could impact the company's financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement, direct financial obligations, and unregistered equity sales, all of which carry inherent financial and operational risks.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- June 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39990 (file_number) — Commission File Number
- 11-3430072 (ein) — IRS Employer Identification No.
- 451 D Street, 5th Floor Boston, Massachusetts 02210 (address) — Principal executive offices
- ( 857 ) 209-0050 (phone_number) — Business phone
FAQ
What is the nature of the material definitive agreement entered into by Elicio Therapeutics?
The filing states that Elicio Therapeutics, Inc. entered into a material definitive agreement on June 3, 2025, but the specific details of this agreement are not provided in the provided text.
What type of direct financial obligation was created by Elicio Therapeutics?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement by Elicio Therapeutics, Inc., but the specific details of the obligation are not elaborated in the provided text.
When did Elicio Therapeutics file this 8-K report?
Elicio Therapeutics, Inc. filed this 8-K report on June 4, 2025, with the earliest event reported being June 3, 2025.
What are the key items reported in this 8-K filing?
This 8-K filing reports on the entry into a material definitive agreement, the creation of a direct financial obligation, unregistered sales of equity securities, Regulation FD disclosures, and financial statements and exhibits.
What was Elicio Therapeutics' former company name and when did the name change occur?
Elicio Therapeutics, Inc.'s former company name was Angion Biomedica Corp., and the date of the name change was February 28, 2014.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding Elicio Therapeutics, Inc. (ELTX).